Upcoming event

Tags

Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, ARCHES, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, hormone-sensitive, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PSMA PET/CT, PTEN, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

The surgical learning curve for biochemical recurrence after robot-assisted radical prostatectomy

European Urology Oncology, July 2022

Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial

The LANCET Infectious Diseases 2022 Jul 27, July 2022

Not all adverse pathology features are equal: Identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy

Journal of Urology, July 2022

Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer

Journal of Clinical Pathology, July 2022

Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: A phase II randomized controlled trial

European Urology Oncology, June 2022

Prostate-specific antigen (PSA) and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial

Journal of Urology, June 2022

The impact of 3D models on positive surgical margins after robot-assisted radical prostatectomy

World Journal of Urology, July 2022

Pathological predictors of 18F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy

BJU International, June 2022

Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer: Analysis of NRG Oncology/RTOG 9601

Journal of Clinical Oncology, June 2022

Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen–radioguided surgery

European Urology, June 2022

Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial

Abiraterone and Olaparib for metastatic castration-resistant prostate cancer

NEJM Evidence, June 2022

PreviousNext